Pioneering ECP Immunomodulation for Over 30 Years

One fully dedicated multi-lingual cross-functional team 100% focused on Therakos.

Click on each function to find out more.

Clinical Team

Clinical and Technical Support

Real-time support during instrument setup and patient treatment
Complaint reporting

On-site Training

Basic operator training
Continuous learning:

Advanced or Refreshment training
Blood Prime training

Remote Training

Introduction to ECP, theory, instrument setup and water treatment
Advanced sessions for troubleshooting or remote supervision
Augmented reality tool available

Wetlabs

Interactive educational sessions based on centre-specific needs

E-learning platform with ECP and CELLEX™ System training

Training presentations
Videos
Quizzes

Technical Team

Our Field Technical Service Specialists guarantee fast turnaround times for repairs

Usually within 24 hours for critical repairs (Monday/Friday)
As agreed together for non-critical repairs

Tailor-made intervention to match your requirement, minimise instrument downtime and avoid delay in patient treatments

Preventive Maintenance Planning
New Instrument Installation
Software Upgrade
Technical Service Training

Service Specialists with unique expertise on Therakos systems
A direct and personalised relationship with your Therakos Service Specialists

Customer Service

Order Fulfillment

Same-day dispatch for all orders placed before 2pm UK time
UVADEX^TM orders delivered within 24 hours
Average kit order delivery time: 3 working days, 24 hours delivery available upon request
White Glove Service for your CELLEX^TM instrument needs

Query Management

Coordination and dispatch of your Service Order, Preventative Maintenance and Instrument Installation
Credit note issuance within 24 hours
Administrative queries answered within 24 hours
GDP Compliant and HMRA Compliant

Order Management Services

Ability to accommodate call-off orders
Order reminder notification
PDF and e-Invoicing platform

Contact us

For any enquiries relating to technical and clinical support please contact us at:

Tel: +44 154 860 0009
Tel: 0808 238 6011 (Toll-Free within the UK)

Fax: +44 208 338 0479

ecphelp@therakos.com

7am to 6pm (GMT+1), Monday to Friday

For any administrative enquiries, including product orders, service order follow-up, deliveries and invoicing, please contact us at:

Tel: +44 1784 614060
Tel: 0800 0698136 (Toll-Free within the UK)

Fax: +44 203 744 1022

customerservice.emea.en@mnk.com

8am to 5pm (GMT+1), Monday to Friday

Fill in the form to download the ONE Team leaflet.

Title

*Name

*Surname

*Email

*Institution/Hospital/Place of work

*Country of work

*Compulsory fields

By clicking the box, you are agreeing to the use of your contact details for marketing purposes.

If you would like to learn more about how we collect and manage your data please refer to our privacy policy

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.